Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2024 16:05 ET | Source: AnaptysBio, Inc.

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys to receive $50 million upfront cash payment from Sagard HealthcarePrior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31,...
March 11, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial...
February 29, 2024 09:15 ET | Source: AnaptysBio, Inc.

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
January 31, 2024 09:15 ET | Source: AnaptysBio, Inc.

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
November 27, 2023 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolioIND filing to support clinical development of ANB101 in autoimmune and...
November 07, 2023 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Named a BioSpace 2024 Best Places to Work Winner

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that,...
November 02, 2023 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Initiated a global Phase 2b trial to treat rheumatoid arthritis (RA) with rosnilimab, our PD-1 agonist Initiating in Q4 2023 a global Phase 2 trial to treat ulcerative colitis (UC) with rosnilimab ...
November 01, 2023 09:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
October 11, 2023 09:15 ET | Source: AnaptysBio, Inc.

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced two...
October 09, 2023 08:15 ET | Source: AnaptysBio, Inc.

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering...